Invesco Ltd. raised its holdings in Liquidia Co. (NASDAQ:LQDA - Free Report) by 2,675.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 700,171 shares of the company's stock after acquiring an additional 674,940 shares during the period. Invesco Ltd. owned about 0.83% of Liquidia worth $8,234,000 at the end of the most recent quarter.
A number of other institutional investors have also added to or reduced their stakes in the stock. Barclays PLC increased its position in Liquidia by 265.0% during the 3rd quarter. Barclays PLC now owns 99,984 shares of the company's stock valued at $999,000 after purchasing an additional 72,591 shares during the period. JPMorgan Chase & Co. boosted its stake in Liquidia by 855.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company's stock valued at $2,354,000 after purchasing an additional 210,753 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Liquidia by 9.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 428,570 shares of the company's stock valued at $5,040,000 after acquiring an additional 38,313 shares in the last quarter. Bank of New York Mellon Corp grew its position in Liquidia by 3.3% in the 4th quarter. Bank of New York Mellon Corp now owns 188,584 shares of the company's stock worth $2,218,000 after purchasing an additional 6,034 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Liquidia during the fourth quarter valued at approximately $169,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
LQDA has been the topic of several research reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $25.00 price objective on shares of Liquidia in a research report on Thursday, April 10th. Scotiabank reaffirmed an "outperform" rating on shares of Liquidia in a report on Thursday, March 20th. Finally, HC Wainwright reissued a "buy" rating and set a $29.00 price objective on shares of Liquidia in a report on Thursday, March 20th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $26.63.
Read Our Latest Stock Report on Liquidia
Liquidia Stock Up 0.6 %
LQDA traded up $0.09 during trading on Friday, reaching $14.12. 584,669 shares of the company were exchanged, compared to its average volume of 961,553. The company has a market cap of $1.20 billion, a price-to-earnings ratio of -8.66 and a beta of 0.23. Liquidia Co. has a 12-month low of $8.26 and a 12-month high of $16.81. The company's 50-day moving average is $14.40 and its two-hundred day moving average is $12.91.
Liquidia (NASDAQ:LQDA - Get Free Report) last issued its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.08). Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. The firm had revenue of $2.92 million for the quarter, compared to analysts' expectations of $4.60 million. Equities analysts forecast that Liquidia Co. will post -1.51 earnings per share for the current year.
Insider Buying and Selling at Liquidia
In other Liquidia news, insider Jason Adair sold 1,856 shares of the firm's stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $13.57, for a total transaction of $25,185.92. Following the sale, the insider now owns 184,304 shares in the company, valued at $2,501,005.28. This trade represents a 1.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, General Counsel Russell Schundler sold 5,964 shares of the stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $13.57, for a total value of $80,931.48. Following the transaction, the general counsel now owns 570,301 shares in the company, valued at $7,738,984.57. This trade represents a 1.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 33,128 shares of company stock valued at $450,072 in the last 90 days. Corporate insiders own 30.10% of the company's stock.
Liquidia Profile
(
Free Report)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Featured Articles
Before you consider Liquidia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Liquidia wasn't on the list.
While Liquidia currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
